Celcuity LLC (CELC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celcuity LLC (CELC) has a cash flow conversion efficiency ratio of -0.383x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.82 Million) by net assets ($116.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Celcuity LLC (CELC) net asset quality to measure how much of total assets are equity-financed.
Celcuity LLC - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Celcuity LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Celcuity LLC (CELC) long-term investment share to see how much of total assets are deployed in long-term investments.
Celcuity LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celcuity LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kumba Iron Ore Ltd
JSE:KIO
|
0.169x |
|
Bancolombia S.A
F:BXK
|
0.267x |
|
Murphy Oil Corporation
NYSE:MUR
|
0.061x |
|
Axos Financial Inc
NYSE:AX
|
0.042x |
|
Yonyou Network Technology Co Ltd
SHG:600588
|
-0.001x |
|
MDA Ltd
TO:MDA
|
0.033x |
|
Hannon Armstrong Sustainable Infrastructure Capital Inc
NYSE:HASI
|
6.160x |
|
Argo Investments Ltd
AU:ARG
|
0.016x |
Annual Cash Flow Conversion Efficiency for Celcuity LLC (2015–2024)
The table below shows the annual cash flow conversion efficiency of Celcuity LLC from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see CELC stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $115.62 Million | $-83.47 Million | -0.722x | -87.51% |
| 2023-12-31 | $139.77 Million | $-53.81 Million | -0.385x | -43.03% |
| 2022-12-31 | $133.77 Million | $-36.01 Million | -0.269x | +8.94% |
| 2021-12-31 | $68.71 Million | $-20.31 Million | -0.296x | +51.59% |
| 2020-12-31 | $11.70 Million | $-7.15 Million | -0.611x | -96.43% |
| 2019-12-31 | $19.30 Million | $-6.00 Million | -0.311x | -29.68% |
| 2018-12-31 | $25.35 Million | $-6.08 Million | -0.240x | -52.07% |
| 2017-12-31 | $31.39 Million | $-4.95 Million | -0.158x | +69.38% |
| 2016-12-31 | $5.61 Million | $-2.89 Million | -0.515x | -30.48% |
| 2015-12-31 | $5.02 Million | $-1.98 Million | -0.394x | -- |
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2… Read more